205 related articles for article (PubMed ID: 37878808)
61. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
[TBL] [Abstract][Full Text] [Related]
62. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Paul B; Rodriguez C; Usmani SZ
Drugs; 2022 Apr; 82(6):613-631. PubMed ID: 35412114
[TBL] [Abstract][Full Text] [Related]
63. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
Pan D; Richter J
Cancer Manag Res; 2023; 15():741-751. PubMed ID: 37497430
[TBL] [Abstract][Full Text] [Related]
64. Elranatamab: First Approval.
Dhillon S
Drugs; 2023 Nov; 83(17):1621-1627. PubMed ID: 37924427
[TBL] [Abstract][Full Text] [Related]
65. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
[TBL] [Abstract][Full Text] [Related]
66. Effective anti-BCMA retreatment in multiple myeloma.
Gazeau N; Beauvais D; Yakoub-Agha I; Mitra S; Campbell TB; Facon T; Manier S
Blood Adv; 2021 Aug; 5(15):3016-3020. PubMed ID: 34351389
[TBL] [Abstract][Full Text] [Related]
67. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
68. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8
Bae J; Parayath N; Ma W; Amiji M; Munshi N; Anderson KC
Leukemia; 2020 Jan; 34(1):210-223. PubMed ID: 31427721
[TBL] [Abstract][Full Text] [Related]
69. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
70. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.
Khanam R; Faiman B; Batool S; Najmuddin MM; Usman R; Kuriakose K; Ahmed A; Rehman MEU; Roksana Z; Syed Z; Anwer F; Raza S
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685606
[TBL] [Abstract][Full Text] [Related]
71. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
72. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.
Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA
Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345
[TBL] [Abstract][Full Text] [Related]
73. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Van Oekelen O; Nath K; Mouhieddine TH; Farzana T; Aleman A; Melnekoff DT; Ghodke-Puranik Y; Shah GL; Lesokhin A; Giralt S; Thibaud S; Rossi A; Rodriguez C; Sanchez L; Richter J; Richard S; Cho HJ; Chari A; Usmani SZ; Jagannath S; Shah UA; Mailankody S; Parekh S
Blood; 2023 Feb; 141(7):756-765. PubMed ID: 36327160
[TBL] [Abstract][Full Text] [Related]
74. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Leuk Lymphoma; 2024 May; 65(5):660-668. PubMed ID: 38347747
[TBL] [Abstract][Full Text] [Related]
75. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract][Full Text] [Related]
76. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].
Sun Q; Qi YK; Qi KM; Yan ZL; Cheng H; Chen W; Zhu F; Sang W; Li DP; Cao J; Shi M; Li ZY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):832-837. PubMed ID: 38049335
[No Abstract] [Full Text] [Related]
77. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract][Full Text] [Related]
78. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S; Lin SXW; Pillarisetti K; Banerjee A; Stephenson T; Ma X; Shetty S; Yang TY; Hilder BW; Jiao Q; Hanna B; Adams HC; Sun YN; Sharma A; Smit J; Infante JR; Goldberg JD; Elsayed Y
Target Oncol; 2022 Jul; 17(4):433-439. PubMed ID: 35749004
[TBL] [Abstract][Full Text] [Related]
79. Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma.
Rinaldi I; Muthalib A; Edina BC; Wiyono L; Winston K
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884566
[TBL] [Abstract][Full Text] [Related]
80. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Curr Med Res Opin; 2024 Feb; 40(2):199-207. PubMed ID: 38078866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]